The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies

Behrmann, Lena; Wellbrock, Jasmin; Fiedler, Walter

doi:10.1080/14728222.2020.1744850

Cited by 12 publications

(13 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, we The reason could be that higher IER3 expression might suppress apoptosis and cause uncontrolled proliferation of neoplastic cells leading to AML. 10,15 Regarding the correlation of IER3 expression with clinical characteristics of leukemia disease, as shown by a previous study, dysregulated IERS has relation with karyotypes in MDS patients. 10 According to our study, positive correlation was discovered in IER3 expression with FLT3-ITD mutation in AML patients.…”

Section: Discussionmentioning

confidence: 88%

IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients

Zhang

Xiang

et al. 2021

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients

Zhang

Xiang

et al. 2021

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…During leukemic transformation, LSCs deploy various molecules and immune suppressor cytokines to alter vital regulatory mechanisms within the BM microenvironment [ 61 ], leading to failure of the immune system to maintain normal hematopoiesis [ 61 ]. LSCs escape the effects of cytotoxic agents by nesting in hematopoietic niches within the BM microenvironment [ 53 , 62 ].…”

Section: Resistancementioning

confidence: 99%

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia

Bolandi

Pakjoo

Beigi

et al. 2021

Cells

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms against currently available drugs helps to recognize the therapeutic obstacles. Various mechanisms of resistance to chemotherapy or targeted inhibitors have been described for AML cells, including a role for the bone marrow niche in both the initiation and persistence of the disease, and in drug resistance of the leukemic stem cell (LSC) population. The BM niche supports LSC survival through direct and indirect interactions among the stromal cells, hematopoietic stem/progenitor cells, and leukemic cells. Additionally, the BM niche mediates changes in metabolic and signal pathway activation due to the acquisition of new mutations or selection and expansion of a minor clone. This review briefly discusses the role of the BM microenvironment and metabolic pathways in resistance to therapy, as discovered through AML clinical studies or cell line and animal models.

show abstract

“…Returning to malignancies, although MSCs have shown therapeutic properties mainly by their potentials for trans-differentiation, immunomodulation, and apoptosis induction [ 2 , 20 , 21 ], their pathogenic, leukemogenic and pro-survival effects in hematologic malignancies are indisputable [ 22 , 23 ]. Cellular mechanisms include RNA processing, ubiquitin–proteasome pathway, cell cycle regulation, cellular stress and non-canonical Wnt signaling are modulated in the leukemia cell lines co-cultured with MSCs [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

The mechanisms of mutual relationship between malignant hematologic cells and mesenchymal stem cells: Does it contradict the nursing role of mesenchymal stem cells?

et al. 2022

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are known as the issue in biology because of some unpredictable characteristics in the different microenvironments especially in their bone marrow niche. MSCs are used in the regenerative medicine because of their unique potentials for trans-differentiation, immunomodulation, and paracrine capacity. But, their pathogenic and pro-survival effects in tumors/cancers including hematologic malignancies are indisputable. MSCs and/or their derivatives might be involved in tumor growth, metastasis and drug resistance in the leukemias. One of important relationship is MSCs and hematologic malignancy-derived cells which affects markedly the outcome of disease. The communication between these two cells may be contact-dependent and/or contact-independent. In this review, we studied the crosstalk between MSCs and malignant hematologic cells which results the final feedback either the progression or suppression of blood cell malignancy. Graphical abstract

show abstract

The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies

Cited by 12 publications

References 128 publications

IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients

IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia

The mechanisms of mutual relationship between malignant hematologic cells and mesenchymal stem cells: Does it contradict the nursing role of mesenchymal stem cells?

Contact Info

Product

Resources

About